Skip to main content

Table 1 Demographics by disease progression in a national, representative cohort of referred patients with chronic kidney disease

From: Low renal replacement therapy incidence among slowly progressing elderly chronic kidney disease patients referred to nephrology care: an observational study

Demographics Progressors
N = 2,924 (33.3%)
Non-progressors
N = 5,847 (66.6%)
Age, median 69.9 (59.3–78.7) 73.4 (64.2–80.6)
 <65 years 1,091 (37.3%) 1,568 (26.8%)
 65- < 75 years 767 (26.2%) 1,683 (28.8%)
 ≥75 years 1,066 (36.5%) 2,596 (44.4%)
Men 1,931 (66.0%) 3,670 (62.8%)
Primary renal disease
 Hypertension/renovascular 732 (25.0%) 1,538 (26.3%)
 Diabetes nephropathy 721 (24.7%) 1,071 (18.3%)
 Glomerulonephritis 315 (10.8%) 600 (10.3%)
 Other specified disease 618 (21.1%) 1,199 (20.5%)
 Unknown 538 (18.4%) 1,439 (24.6%)
Progression rate (% decline in ml/min/1.73 m2 per year) −31.9 (−43.9––24.5) 0.60 (−8.8–14.6)
Progression rate (absolute change in ml/min/1.73 m2 per year) −6.1 (−8.6––4.3) 0.13 (−1.8–3.0)
Chronic Kidney Disease Stage
 G3b 56 (1.9%) 1,434 (24.5%)
 G4 1,117 (38.2%) 3,570 (61.1%)
 G5 1,751 (59.9%) 843 (14.4%)
Comorbidity at baseline
 Diabetes 1,172 (40.1%) 2,118 (36.2%)
 Cardiovascular disease 1,109 (37.9%) 2,205 (37.7%)
 Dementia 24 (0.8%) 57 (1.0%)
 Chronic pulmonary disease 217 (7.4%) 483 (8.3%)
 Cancer 414 (14.2%) 1,011 (17.3%)
Charlson score above kidney disease median (IQR) 1.0 (0.00–2.0) 1.0 (0.0–2.0)
Current medication
 ESA use [n = 7221] 680 (23.3%) 1,062 (18.2%)
 Antihypertensives number of, median (IQR) 3.0 (2.0–4.0) 3.0 (2.0–4.0)
 Protein restricted diet use 436 (14.9%) 545 (9.3%)
 Diuretics use 2,148 (73.5%) 3,974 (68.0%)
 Statin use 1,311 (44.8%) 2,727 (46.6%)
 Vitamin-D supplements use 1,770 (60.5%) 3,005 (51.4%)
 Iron use
 intravenous 286 (9.8%) 425 (7.3%)
 oral 524 (17.9%) 853 (14.6%)
Laboratory data
 P-Albumin (g/l): [n = 8177] 36.0 (33.0–39.0) 37.0 (35.0–40.00=)
 S-Calcium (mmol/l): [n = 7578] 2.28 (2.17–2.37) 2.31 (2.23–2.39)
 CRP (mmol/l): [n = 5723] 5.0 (2.8–10.0) 5.0 (2.5–10.0)
 P-Phosphate (mmol/l): [n = 7997] 1.5 (1.3–1.8) 1.2 (1.1–1.4)
 S-Creatinine (mmol/l): 355 (272–475) 217 (177–268)
 B-Hemoglobin (g/l): [n = 8537] 117 (108–127) 125 (116–135)
 S-PTH (ng/ml): [n = 5818] 21.0 (12.9–33.7)) 14.2 (9.5–21.8)
 U-Albumin/creatinine ratio (mg/mmol) [n = 3149] 40.1 (9.4–170.9) 12.0 (2.5–48.0)
 eGFR (ml/min/1.73 m2): 13.3 (9.4–18.2) 23.6 (18.0–29.9)
Clinical information
 Mean arterial pressure (median mmHg, IQR) [n = 8159] 97.6 (90.0–106.6) 96.0 (88.3–103.3)
 Pulse pressure (median mmHg, IQR) [n = 8159] 60.0 (50.0–75.0) 60.0 (49.0–70.0)
BMI (IQR) [n = 6432]
 <18.5 Kg/m2 27 (0.9%) 61 (1.0%)
 18.5–25 Kg/m2 733 (25.1%) 1,344 (23.0%)
 25–30 Kg/m2 781 (26.7%) 1,630 (27.9%)
 >30 Kg/m2 640 (21.9%) 1,216 (20.8%)
Region
 Lower North 676 (23.1%) 1,319 (22.6%)
 South 405 (13.9%) 777 (13.3%)
 Southeast 356 (12.2%) 600 (10.3%)
 Southwest 514 (17.6%) 1,166 (19.9%)
 Upper North 151 (5.2%) 269 (4.6%)
 Stockholm 822 (28.1%) 1,716 (29.4%)
University Hospital 1,192 (40.8%) 2,381 (40.7%)
  1. All categorical values are expressed as numbers (n) and percentage (%). All continuous variables are expressed as median and interquartile range (IQR). Erythropoietin stimulating agents (ESA), estimated glomerular filtration rate (eGFR), Serum (S), Plasma (P), Blood (B), and Urine (U). To convert Calcium in mmol/l to mg/dL divide by 0.2495. To convert Phosphate mmol/l to mg/dL multiply with 3.0974. To convert Hemoglobin in g/l to g/dL divide by 10. To convert creatinine from micromole/l to mg/dL multiply by 0.0113